Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

BeyondSpring Inc. (BYSI)

2.53   -0.03 (-1.17%) 01-27 16:00
Open: 2.55 Pre. Close: 2.56
High: 2.67 Low: 2.5
Volume: 161,345 Market Cap: 98(M)

Technical analysis

as of: 2023-01-27 4:43:10 PM
Overall:       
Stoxline posted a SELL today, upgraded from strong sell. Downward movement continues, but could change at any time.
Target: Six months: 3.49     One year: 4.07
Support: Support1: 2.01    Support2: 1.41
Resistance: Resistance1: 2.99    Resistance2: 3.49
Pivot: 2.31
Moving Average: MA(5): 2.62     MA(20): 2.19
MA(100): 1.23     MA(250): 1.58
MACD: MACD(12,26): 0.3     Signal(9): 0.3
Stochastic oscillator: %K(14,3): 67.7     %D(3): 73.1
RSI: RSI(14): 62.2
52-week: High: 3.31  Low: 0.54
Average Vol(K): 3-Month: 1,034 (K)  10-Days: 543 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ BYSI ] has closed below upper band by 32.6%. Bollinger Bands are 70.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 10 days. This is a sign that the current trend might continue.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 2.67 - 2.69 2.69 - 2.71
Low: 2.45 - 2.48 2.48 - 2.5
Close: 2.5 - 2.53 2.53 - 2.55

Company Description

BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of NSCLC; nivolumab and ipilimumab, a CTLA-4 antibody for the treatment of SCLC; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform. The company was founded in 2010 and is headquartered in New York, New York.

Headline News

Wed, 25 Jan 2023
CapitalGainsReport: Biotech Stocks To Watch in 2023: PBIO, BYSI ... - Marketscreener.com

Thu, 19 Jan 2023
Healthcare Stocks on the Move Thursday: NRSN, PBIO, BYSI, SY, SRDX, TCBP, OLK, ABSI - InvestorsObserver

Thu, 19 Jan 2023
Buyers Jump Aside as Stocks Continue to Fall - RealMoney

Thu, 12 Jan 2023
Do Analysts Agree Thursday on Beyondspring Inc (BYSI) Stock's Target Price? - InvestorsObserver

Tue, 10 Jan 2023
BeyondSpring regains Nasdaq compliance on minimum bid price ... - Seeking Alpha

Tue, 03 Jan 2023
Morningstar's Best- and Worst-Performing Stocks: 2022 - Morningstar

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 39 (M)
% Held by Insiders 2.309e+007 (%)
% Held by Institutions 40.5 (%)
Shares Short 2,400 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -6.618e+007
EPS Est Next Qtl -0.55
EPS Est This Year -3.77
EPS Est Next Year -3.1
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -4
Return on Assets (ttm) 903
Return on Equity (ttm) -41.7
Qtrly Rev. Growth 1.35e+006
Gross Profit (p.s.) 95.43
Sales Per Share -125.45
EBITDA (p.s.) 1.46739e+006
Qtrly Earnings Growth -1.7
Operating Cash Flow 0 (M)
Levered Free Cash Flow -47 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.03
Price to Cash Flow 3.37

Stock Dividends

Dividend 0
Forward Dividend 2.93e+006
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.